← All trials
NCT04485156
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2020
- Primary completion
- Aug 31, 2025
- Completion date
- Dec 31, 2026
- First posted
- Jul 24, 2020
- Last posted
- Jul 24, 2020
- Enrollment
- 926
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Seoul National UniversityLead sponsor
- Seoul National UniversityCollaborator
- Seoul National UniversityCollaborator
- Seoul National UniversityCollaborator
- Yonsei UniversityCollaborator
- Government of KoreaCollaborator
- Korean Institute of TuberculosisCollaborator
- Chonnam National UniversityCollaborator
- Pusan National UniversityCollaborator
- Pusan National UniversityCollaborator
- International Tuberculosis Research CenterCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.